Castelldefels

Researchers are evaluating whether a special gingivitis toothpaste can improve gum inflammation in adults aged 18 to 65 years. The study compares this toothpaste to a regular toothpaste to see if it helps reduce signs of gingivitis and also assesses the safety of the product. Participants must have moderate gum inflammation and dental plaque to join the study. Participants will be assigned to use either the gingivitis toothpaste or the regular toothpaste two to three times daily for four weeks. They will visit the clinic on scheduled days during this period for check-ups and evaluations. The study aims to observe changes in gum health over this one-month treatment period. During the study, participants will undergo clinical evaluations to measure gum inflammation using the Gingival Index. Researchers will monitor adherence to the toothpaste use and collect data on safety and effectiveness. The main outcome is the change in gingival health from the start to the end of the one-month treatment period.

Researchers are evaluating the safety and effectiveness of a single infusion of anti-COVID-19 hyperimmune intravenous immunoglobulin (hIVIG) compared to a placebo in adults recently diagnosed with SARS-CoV-2 infection who do not need hospitalization. This Phase 3, double-blind, randomized trial aims to assess participants' clinical status seven days after treatment using a five-category scale ranging from no symptoms to critical illness or death. The study also examines outcomes in two groups: those receiving other approved antiviral treatments and those who are not. Participants receive either a single 3.5-gram infusion of hIVIG or a 35-milliliter infusion of saline placebo, with equal chance of assignment to each group. The randomization is stratified by study site and whether participants are receiving standard antiviral care. The infusion occurs once, and participants are monitored thereafter to compare the effects of hIVIG plus standard care versus placebo plus standard care. During the study, participants provide written consent and agree to follow study procedures through 28 days. Researchers assess clinical status seven days after infusion and track safety and disease progression. The study excludes those with prior immune therapies or certain medical conditions and requires participants to avoid other COVID-19 treatment trials through Day 7 unless hospitalized or experiencing significant disease worsening. Clinical assessments and monitoring continue to ensure participant safety and capture outcomes related to COVID-19 illness severity.